<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="132809">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01900678</url>
  </required_header>
  <id_info>
    <org_study_id>VLIC-USA</org_study_id>
    <secondary_id>CIV-13-04-010581</secondary_id>
    <nct_id>NCT01900678</nct_id>
  </id_info>
  <brief_title>A Study of the Safety and Efficacy of the VytronUS Low-Intensity Collimated Ultrasound Ablation System</brief_title>
  <official_title>VLIC-USA: A Single-Center Study of the Safety and Efficacy of the VytronUS Low-Intensity Collimated Ultrasound Ablation System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VytronUS, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VytronUS, Inc.</source>
  <oversight_info>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this investigation is to evaluate whether pulmonary vein isolation using
      the VytronUS ablation system is safe and effective acutely and at 3 months.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Device or procedure related adverse events.</measure>
    <time_frame>Three months post procedure.</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pulmonary vein isolation.</measure>
    <time_frame>Three months post procedure.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Paroxysmal Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>VytronUS Ablation System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with the VytronUS Ablation System.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VytronUS Ablation System</intervention_name>
    <description>Pulmonary vein isolation.</description>
    <arm_group_label>VytronUS Ablation System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 to 70 years old.

          -  Recurrent symptomatic paroxysmal atrial fibrillation refractory to at least  one
             antiarrhythmic drug.

        Exclusion Criteria:

          -  Prior pulmonary vein isolation

          -  Presence of intracardiac thrombus

          -  Indication of inaccessible pulmonary or cardiac anatomy

          -  Myocardial infarction, PCI, or cardiac surgery in prior three months

          -  Moderate to severe valvular disease or prior valve replacement

          -  NYHA Class IV

          -  LVEF &lt; 40%

          -  Previous stroke or TIA

          -  Serum creatinine &gt; 2.5mg/dL or allergy to intravenous contrast agents

          -  Existing bleeding diathesis or history of complications with anticoagulation therapy

          -  Women who are nursing, pregnant, or trying to become pregnant

          -  Subjects unwilling or unable to provide consent

          -  Participation in a drug or device trial that would prevent completion of required
             study procedures

          -  Active implantable devices

          -  Major organ system disease
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Petr Neuzil, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Na Homolce Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christopher Schneider</last_name>
    <phone>408-730-1333</phone>
    <email>cschneider@vytronus.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Na Homolce Hospital</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Libor Machalek</last_name>
      <phone>+420 2 257 252 144</phone>
      <email>libor.machalek@homolka.cz</email>
    </contact>
    <investigator>
      <last_name>Petr Neuzil, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vivek Reddy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Czech Republic</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 11, 2013</lastchanged_date>
  <firstreceived_date>July 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
